Daraxonrasib, which nearly doubled patients' survival time, fights the disease in a new way. It bear-hugs a cancer protein that drives cell growth.

From special pens to earwax evaluations, a plethora of emerging diagnostics could one day be a major boon for people with the debilitating disease.